LIVIVO - Search results -

Search results

Result 1 - 7 of total 7

Search options

Article ; Online: #BCSM and #breastcancer: Contemporary cancer-specific online social media communities.

Platt, James R / Brady, Richard R

2019 Volume 26, Issue 4, Page(s) 729–733

Abstract: Online health care communities are commonplace on social media. This report investigates the engagement and use of breast cancer-specific hashtags: #BCSM and #breastcancer. With over 5 million Twitter impressions weekly and increased engagement around ... ...

Abstract	Online health care communities are commonplace on social media. This report investigates the engagement and use of breast cancer-specific hashtags: #BCSM and #breastcancer. With over 5 million Twitter impressions weekly and increased engagement around academic meetings and news releases, these communities connect a global population. Most participants are based in the USA and work in health care; however, there is also significant engagement from the general population. Improved understanding of online hashtag communities and their output will allow us to innovate and improve the utility of this popular medium for communication in breast cancer and other disease-specific populations.
MeSH term(s)	Breast Neoplasms ; Communication ; Female ; Humans ; Social Media
Language	English
Publishing date	2019-09-06
Publishing country	United States
Document type	Journal Article
ZDB-ID	1289960-4
ISSN	1524-4741 ; 1075-122X
ISSN (online)	1524-4741
ISSN	1075-122X
DOI	10.1111/tbj.13576
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4483: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: The impact of mismatch repair status and systemic inflammatory markers on radiological staging in colon cancer.

Platt, James R / Ansett, Jennifer / Seligmann, Jenny F / West, Nicholas P / Tolan, Damian J M

The British journal of radiology

2023 Volume 96, Issue 1150, Page(s) 20230098

Abstract: Objective: Mismatch repair (MMR) deficient (dMMR) colon cancer (CC) is distinct from MMR proficient (pMMR) CC, yet the impact of MMR status on radiological staging is unclear. The purpose of this study was to investigate how MMR status impacts CC CT ... ...

Abstract	Objective: Mismatch repair (MMR) deficient (dMMR) colon cancer (CC) is distinct from MMR proficient (pMMR) CC, yet the impact of MMR status on radiological staging is unclear. The purpose of this study was to investigate how MMR status impacts CC CT staging. Methods: We retrospectively compared CT staging accuracy between dMMR and pMMR CC patients undergoing curative resection. Accuracy was assessed as individual tumour (T)/nodal (N) stages and as dichotomous "statuses" (T1/2 Results: There was no significant difference in overall staging accuracy between the dMMR (44 patients) and pMMR (57 patients) groups. dMMR tumours with incorrect N stage/"status" were more likely to be overstaged than pMMR tumours (90% Conclusion: Whilst overall staging accuracy was similar between groups, incorrectly N staged dMMR tumours were more likely to be overstaged than pMMR tumours, risking inappropriate surgical or neoadjuvant treatment. We describe novel relationships between several inflammatory markers and pathological "N status" in dMMR CC, which if integrated into routine practice may improve CT staging accuracy. Advances in knowledge: Compared to pMMR CC, dMMR CC is at significant risk of N overstaging. Platelet count, CRP and neutrophil count are higher in dMMR CC patients with nodal metastases than those without, and their role in refining clinical staging requires further investigation.
MeSH term(s)	Humans ; Retrospective Studies ; DNA Mismatch Repair ; Neoplasm Staging ; Colonic Neoplasms/diagnostic imaging ; Colonic Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Prognosis
Language	English
Publishing date	2023-07-26
Publishing country	England
Document type	Journal Article
ZDB-ID	2982-8
ISSN	1748-880X ; 0007-1285
ISSN (online)	1748-880X
ISSN	0007-1285
DOI	10.1259/bjr.20230098
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ue I Zs.11: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Personalizing neoadjuvant chemotherapy for locally advanced colon cancer: protocols for the international phase III FOxTROT2 and FOxTROT3 randomized controlled trials.

Platt, James R / Williams, Christopher J M / Craig, Zoe / Cairns, David A / Glasbey, James C / Morton, Dion / Seligmann, Jenny

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

2023 Volume 25, Issue 3, Page(s) 357–366

Abstract: Aim: FOxTROT1 established a new standard of care for managing locally advanced colon cancer (CC) with neoadjuvant chemotherapy (NAC). Six weeks of neoadjuvant oxaliplatin and fluoropyrimidine (OxFp) chemotherapy was associated with greater 2-year ... ...

Abstract	Aim: FOxTROT1 established a new standard of care for managing locally advanced colon cancer (CC) with neoadjuvant chemotherapy (NAC). Six weeks of neoadjuvant oxaliplatin and fluoropyrimidine (OxFp) chemotherapy was associated with greater 2-year disease-free survival (DFS) when compared with proceeding straight to surgery (STS). There is now a need to refine the use of NAC and identify those most likely to benefit. FOxTROT2 will aim to investigate NAC in older adults and those with frailty. FOxTROT3 will aim to assess whether intensified triplet NAC provides additional benefits over OxFp. Method: FOxTROT2 and FOxTROT3 are international, open-label, phase III randomized controlled trials. Eligible patients will be identified by the multidisciplinary team. Patient age, frailty and comorbidities will be considered to guide trial entry. Participants will be randomized 2:1 to the intervention or control arm: 6 weeks of dose-adapted neoadjuvant OxFp versus STS in FOxTROT2 and 6 weeks of neoadjuvant modified oxaliplatin, 5-fluorouracil and irinotecan versus OxFp in FOxTROT3. The primary endpoint in FOxTROT2 is 3-year DFS. In FOxTROT3, tumour regression grade and 3-year DFS are co-primary endpoints. Discussion: FOxTROT2 and FOxTROT3 will establish the FOxTROT platform, a key part of our long-term strategy to develop neoadjuvant treatments for CC. FOxTROT2 will investigate NAC in a population under-represented in FOxTROT1 and wider research. FOxTROT3 will assess whether it is possible to induce greater early tumour responses and whether this translates to superior long-term outcomes. Looking ahead, the FOxTROT platform will facilitate further trial comparisons and extensive translational research to optimize the use of NAC in CC.
MeSH term(s)	Aged ; Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemotherapy, Adjuvant/methods ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/surgery ; Fluorouracil/therapeutic use ; Frailty ; Neoadjuvant Therapy/methods ; Neoplasm Staging ; Oxaliplatin/therapeutic use ; Randomized Controlled Trials as Topic ; Clinical Trials, Phase III as Topic
Chemical Substances	Fluorouracil (U3P01618RT) ; Oxaliplatin (04ZR38536J)
Language	English
Publishing date	2023-02-15
Publishing country	England
Document type	Clinical Trial Protocol ; Journal Article
ZDB-ID	1440017-0
ISSN	1463-1318 ; 1462-8910
ISSN (online)	1463-1318
ISSN	1462-8910
DOI	10.1111/codi.16487
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5799: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP).

Starkey, Thomas / Ionescu, Maria C / Tilby, Michael / Little, Martin / Burke, Emma / Fittall, Matthew W / Khan, Sam / Liu, Justin K H / Platt, James R / Mew, Rosie / Tripathy, Arvind R / Watts, Isabella / Williams, Sophie Therese / Appanna, Nathan / Al-Hajji, Youssra / Barnard, Matthew / Benny, Liza / Burnett, Alexander / Bytyci, Jola /

Cattell, Emma L / Cheng, Vinton / Clark, James J / Eastlake, Leonie / Gerrand, Kate / Ghafoor, Qamar / Grumett, Simon / Harper-Wynne, Catherine / Kahn, Rachel / Lee, Alvin J X / Lomas, Oliver / Lydon, Anna / Mckenzie, Hayley / Panneerselvam, Hari / Pascoe, Jennifer S / Patel, Grisma / Patel, Vijay / Potter, Vanessa A / Randle, Amelia / Rigg, Anne S / Robinson, Tim M / Roylance, Rebecca / Roques, Tom W / Rozmanowski, Stefan / Roux, René L / Shah, Ketan / Sheehan, Remarez / Sintler, Martin / Swarup, Sanskriti / Taylor, Harriet / Tillett, Tania / Tuthill, Mark / Williams, Sarah / Ying, Yuxin / Beggs, Andrew / Iveson, Tim / Lee, Siow Ming / Middleton, Gary / Middleton, Mark / Protheroe, Andrew / Fowler, Tom / Johnson, Peter / Lee, Lennard Y W

Scientific reports

2023 Volume 13, Issue 1, Page(s) 11327

Abstract: Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not ... ...

Abstract	Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.
MeSH term(s)	Humans ; Male ; Female ; Case-Control Studies ; Treatment Outcome ; Neoplasms/complications ; Neoplasms/epidemiology ; COVID-19/complications ; COVID-19/epidemiology ; England/epidemiology ; Adolescent ; Young Adult ; Adult ; Middle Aged ; Aged ; Aged, 80 and over
Language	English
Publishing date	2023-07-25
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-023-36990-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation.

Lee, Lennard Y W / Tilby, Michael / Starkey, Thomas / Ionescu, Maria C / Burnett, Alex / Hattersley, Rosie / Khan, Sam / Little, Martin / Liu, Justin K H / Platt, James R / Tripathy, Arvind / Watts, Isabella / Williams, Sophie Therese / Appanna, Nathan / Al-Hajji, Youssra / Barnard, Matthew / Benny, Liza / Buckley, Andrew / Cattell, Emma /

Cheng, Vinton / Clark, James / Eastlake, Leonie / Gerrand, Kate / Ghafoor, Qamar / Grumett, Simon / Harper-Wynne, Catherine / Kahn, Rachel / Lee, Alvin J X / Lydon, Anna / McKenzie, Hayley / Panneerselvam, Hari / Pascoe, Jennifer / Patel, Grisma / Patel, Vijay / Potter, Vanessa / Randle, Amelia / Rigg, Anne S / Robinson, Tim / Roylance, Rebecca / Roques, Tom / Rozmanowski, Stefan / Roux, René L / Shah, Ketan / Sintler, Martin / Taylor, Harriet / Tillett, Tania / Tuthill, Mark / Williams, Sarah / Beggs, Andrew / Iveson, Tim / Lee, Siow Ming / Middleton, Gary / Middleton, Mark / Protheroe, Andrew S / Fittall, Matthew W / Fowler, Tom / Johnson, Peter

JAMA oncology

2022 Volume 9, Issue 2, Page(s) 188–196

Abstract: Importance: Accurate identification of patient groups with the lowest level of protection following COVID-19 vaccination is important to better target resources and interventions for the most vulnerable populations. It is not known whether SARS-CoV-2 ... ...

Abstract	Importance: Accurate identification of patient groups with the lowest level of protection following COVID-19 vaccination is important to better target resources and interventions for the most vulnerable populations. It is not known whether SARS-CoV-2 antibody testing has clinical utility for high-risk groups, such as people with cancer. Objective: To evaluate whether spike protein antibody vaccine response (COV-S) following COVID-19 vaccination is associated with the risk of SARS-CoV-2 breakthrough infection or hospitalization among patients with cancer. Design, setting, and participants: This was a population-based cross-sectional study of patients with cancer from the UK as part of the National COVID Cancer Antibody Survey. Adults with a known or reported cancer diagnosis who had completed their primary SARS-CoV-2 vaccination schedule were included. This analysis ran from September 1, 2021, to March 4, 2022, a period covering the expansion of the UK's third-dose vaccination booster program. Interventions: Anti-SARS-CoV-2 COV-S antibody test (Elecsys; Roche). Main outcomes and measures: Odds of SARS-CoV-2 breakthrough infection and COVID-19 hospitalization. Results: The evaluation comprised 4249 antibody test results from 3555 patients with cancer and 294 230 test results from 225 272 individuals in the noncancer population. The overall cohort of 228 827 individuals (patients with cancer and the noncancer population) comprised 298 479 antibody tests. The median age of the cohort was in the age band of 40 and 49 years and included 182 741 test results (61.22%) from women and 115 737 (38.78%) from men. There were 279 721 tests (93.72%) taken by individuals identifying as White or White British. Patients with cancer were more likely to have undetectable anti-S antibody responses than the general population (199 of 4249 test results [4.68%] vs 376 of 294 230 [0.13%]; P < .001). Patients with leukemia or lymphoma had the lowest antibody titers. In the cancer cohort, following multivariable correction, patients who had an undetectable antibody response were at much greater risk for SARS-CoV-2 breakthrough infection (odds ratio [OR], 3.05; 95% CI, 1.96-4.72; P < .001) and SARS-CoV-2-related hospitalization (OR, 6.48; 95% CI, 3.31-12.67; P < .001) than individuals who had a positive antibody response. Conclusions and relevance: The findings of this cross-sectional study suggest that COV-S antibody testing allows the identification of patients with cancer who have the lowest level of antibody-derived protection from COVID-19. This study supports larger evaluations of SARS-CoV-2 antibody testing. Prevention of SARS-CoV-2 transmission to patients with cancer should be prioritized to minimize impact on cancer treatments and maximize quality of life for individuals with cancer during the ongoing pandemic.
MeSH term(s)	Female ; Adult ; Male ; Humans ; Middle Aged ; COVID-19 Vaccines ; Spike Glycoprotein, Coronavirus ; Cross-Sectional Studies ; Antibody Formation ; Quality of Life ; COVID-19/epidemiology ; COVID-19/prevention & control ; SARS-CoV-2 ; Vaccines ; Neoplasms/epidemiology ; Antibodies, Viral ; Delivery of Health Care
Chemical Substances	COVID-19 Vaccines ; spike protein, SARS-CoV-2 ; Spike Glycoprotein, Coronavirus ; Vaccines ; Antibodies, Viral
Language	English
Publishing date	2022-12-22
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2374-2445
ISSN (online)	2374-2445
DOI	10.1001/jamaoncol.2022.5974
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study.

Lee, Lennard Y W / Starkey, Thomas / Ionescu, Maria C / Little, Martin / Tilby, Michael / Tripathy, Arvind R / Mckenzie, Hayley S / Al-Hajji, Youssra / Barnard, Matthew / Benny, Liza / Burnett, Alexander / Cattell, Emma L / Charman, Jackie / Clark, James J / Khan, Sam / Ghafoor, Qamar / Illsley, George / Harper-Wynne, Catherine / Hattersley, Rosie J /

The Lancet. Oncology

2022 Volume 23, Issue 6, Page(s) 748–757

Abstract: Background: People with cancer are at increased risk of hospitalisation and death following infection with SARS-CoV-2. Therefore, we aimed to conduct one of the first evaluations of vaccine effectiveness against breakthrough SARS-CoV-2 infections in ... ...

Abstract	Background: People with cancer are at increased risk of hospitalisation and death following infection with SARS-CoV-2. Therefore, we aimed to conduct one of the first evaluations of vaccine effectiveness against breakthrough SARS-CoV-2 infections in patients with cancer at a population level. Methods: In this population-based test-negative case-control study of the UK Coronavirus Cancer Evaluation Project (UKCCEP), we extracted data from the UKCCEP registry on all SARS-CoV-2 PCR test results (from the Second Generation Surveillance System), vaccination records (from the National Immunisation Management Service), patient demographics, and cancer records from England, UK, from Dec 8, 2020, to Oct 15, 2021. Adults (aged ≥18 years) with cancer in the UKCCEP registry were identified via Public Health England's Rapid Cancer Registration Dataset between Jan 1, 2018, and April 30, 2021, and comprised the cancer cohort. We constructed a control population cohort from adults with PCR tests in the UKCCEP registry who were not contained within the Rapid Cancer Registration Dataset. The coprimary endpoints were overall vaccine effectiveness against breakthrough infections after the second dose (positive PCR COVID-19 test) and vaccine effectiveness against breakthrough infections at 3-6 months after the second dose in the cancer cohort and control population. Findings: The cancer cohort comprised 377 194 individuals, of whom 42 882 had breakthrough SARS-CoV-2 infections. The control population consisted of 28 010 955 individuals, of whom 5 748 708 had SARS-CoV-2 breakthrough infections. Overall vaccine effectiveness was 69·8% (95% CI 69·8-69·9) in the control population and 65·5% (65·1-65·9) in the cancer cohort. Vaccine effectiveness at 3-6 months was lower in the cancer cohort (47·0%, 46·3-47·6) than in the control population (61·4%, 61·4-61·5). Interpretation: COVID-19 vaccination is effective for individuals with cancer, conferring varying levels of protection against breakthrough infections. However, vaccine effectiveness is lower in patients with cancer than in the general population. COVID-19 vaccination for patients with cancer should be used in conjunction with non-pharmacological strategies and community-based antiviral treatment programmes to reduce the risk that COVID-19 poses to patients with cancer. Funding: University of Oxford, University of Southampton, University of Birmingham, Department of Health and Social Care, and Blood Cancer UK.
MeSH term(s)	Adolescent ; Adult ; COVID-19/epidemiology ; COVID-19/prevention & control ; COVID-19 Vaccines ; Case-Control Studies ; Humans ; Neoplasms/epidemiology ; SARS-CoV-2 ; Vaccine Efficacy ; Viral Vaccines
Chemical Substances	COVID-19 Vaccines ; Viral Vaccines
Language	English
Publishing date	2022-05-23
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2049730-1
ISSN	1474-5488 ; 1470-2045
ISSN (online)	1474-5488
ISSN	1470-2045
DOI	10.1016/S1470-2045(22)00202-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5696: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 460: Show issues

Order via subito

Details ▾

Article ; Online: COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study.

Lee, Lennard Y W / Ionescu, Maria C / Starkey, Thomas / Little, Martin / Tilby, Michael / Tripathy, Arvind R / Mckenzie, Hayley S / Al-Hajji, Youssra / Appanna, Nathan / Barnard, Matthew / Benny, Liza / Burnett, Alexander / Cattell, Emma L / Clark, James J / Khan, Sam / Ghafoor, Qamar / Panneerselvam, Hari / Illsley, George / Harper-Wynne, Catherine /

Hattersley, Rosie J / Lee, Alvin Jx / Lomas, Oliver / Liu, Justin Kh / McCauley, Amanda / Pang, Matthew / Pascoe, Jennifer S / Platt, James R / Patel, Grisma / Patel, Vijay / Potter, Vanessa A / Randle, Amelia / Rigg, Anne S / Robinson, Tim M / Roques, Tom W / Roux, René L / Rozmanowski, Stefan / Taylor, Harriet / Tuthill, Mark H / Watts, Isabella / Williams, Sarah / Beggs, Andrew / Iveson, Tim / Lee, Siow M / Middleton, Gary / Middleton, Mark / Protheroe, Andrew / Fittall, Matthew W / Fowler, Tom / Johnson, Peter

European journal of cancer (Oxford, England : 1990)

2022 Volume 175, Page(s) 1–10

Abstract: Purpose: People living with cancer and haematological malignancies are at an increased risk of hospitalisation and death following infection with acute respiratory syndrome coronavirus 2. Coronavirus third dose vaccine boosters are proposed to boost ... ...

Abstract	Purpose: People living with cancer and haematological malignancies are at an increased risk of hospitalisation and death following infection with acute respiratory syndrome coronavirus 2. Coronavirus third dose vaccine boosters are proposed to boost waning immune responses in immunocompromised individuals and increase coronavirus protection; however, their effectiveness has not yet been systematically evaluated. Methods: This study is a population-scale real-world evaluation of the United Kingdom's third dose vaccine booster programme for cancer patients from 8th December 2020 to 7th December 2021. The cancer cohort comprises individuals from Public Health England's national cancer dataset, excluding individuals less than 18 years. A test-negative case-control design was used to assess the third dose booster vaccine effectiveness. Multivariable logistic regression models were fitted to compare risk in the cancer cohort relative to the general population. Results: The cancer cohort comprised of 2,258,553 tests from 361,098 individuals. Third dose boosters were evaluated by reference to 87,039,743 polymerase chain reaction coronavirus tests. Vaccine effectiveness against breakthrough infections, symptomatic infections, coronavirus hospitalisation and death in cancer patients were 59.1%, 62.8%, 80.5% and 94.5%, respectively. Lower vaccine effectiveness was associated with a cancer diagnosis within 12 months, lymphoma, recent systemic anti-cancer therapy (SACT) or radiotherapy. Patients with lymphoma had low levels of protection from symptomatic disease. In spite of third dose boosters, following multivariable adjustment, individuals with cancer remain at an increased risk of coronavirus hospitalisation and death compared to the population control (OR 3.38, 3.01, respectively. p < 0.001 for both). Conclusions: Third dose boosters are effective for most individuals with cancer, increasing protection from coronavirus. However, their effectiveness is heterogenous and lower than the general population. Many patients with cancer will remain at the increased risk of coronavirus infections even after 3 doses. In the case of patients with lymphoma, there is a particularly strong disparity of vaccine effectiveness against breakthrough infection and severe disease. Breakthrough infections will disrupt cancer care and treatment with potentially adverse consequences on survival outcomes. The data support the role of vaccine boosters in preventing severe disease, and further pharmacological intervention to prevent transmission and aid viral clearance to limit the disruption of cancer care as the delivery of care continues to evolve during the coronavirus pandemic.
MeSH term(s)	COVID-19/epidemiology ; COVID-19/prevention & control ; Hospitalization ; Humans ; Neoplasms ; Pandemics ; Vaccination ; Vaccine Efficacy
Language	English
Publishing date	2022-07-13
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2022.06.038
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito